Physician profile
Nilay Shah
NPI 1043472368
$1,703.62
in general payments reported to CMS, 2019-2025
15 companies · $645 in 2025
The $645 reported for 2025 was more than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $16.37 · 2021: $136 · 2022: $614 · 2023: $129 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $774.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $443.22 | 2020-2023 | |
| Mentor Worldwide LLC | $234.76 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Abbvie INC. | $223.50 | 2025 | |
| Motiva USA, LLC | $167.26 | 2025 | |
| Sientra, INC. | $149.98 | 2019 | |
| Acera Surgical, INC. | $141.75 | 2025 | Restrata Wound Matrix |
| Sk Life Science, INC. | $89.03 | 2022 | |
| Ani Pharmaceuticals, INC. | $85.77 | 2022 | |
| Lundbeck LLC | $59.04 | 2022-2023 | Vyepti |
| Aprecia Pharmaceuticals, LLC | $35.97 | 2021 | |
| Almatica Pharma LLC | $17.11 | 2023 | Gralise |
| Genentech USA, INC. | $14.53 | 2025 | Ocrevus Zunovo |
| Adamas Pharmaceuticals, INC. | $14.20 | 2021 | |
| Endo Pharmaceuticals INC. | $14.07 | 2022 | |
| Tela Bio, INC. | $13.43 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nilay Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.